Document Detail


Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent.
MedLine Citation:
PMID:  24036845     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: A variety of anticancer drugs, including doxorubicin and mitoxantrone, have structures in which a DNA-intercalating chromophore is linked to a positively charged side chain. These drugs generally inhibit tumour growth and survival by poisoning the enzyme DNA topoisomerase II. SN 28049, a benzonaphthyridine derivative with these properties, has curative activity against the Colon 38 tumour in mice. Previous pharmacokinetic studies have demonstrated tumour-selective retention with approximately 20-fold higher area under the concentration-time curve (AUC) for tumour tissue as compared to normal tissues. We have investigated here whether such retention is tumour specific.
METHODS: Plasma and tissue pharmacokinetics were assessed in the murine Lewis lung (LL3) tumour in C57 BL/6 mice and in xenografts of the NZM4, NZM10 and NZM52 human melanoma lines in Balb/c Rag-1 immunodeficient mice. The in vitro cellular localisation of SN 28049 in murine and human cell lines was studied by confocal fluorescence microscopy.
RESULTS: A 260-fold variation, from 8.9 μM h (NZM4) to 2,334 μM h (Colon 38), was found among the different tumours. Only small variations were observed in the corresponding plasma AUC (2.9-5 μM h). Moreover, in vivo activity, as measured by tumour growth delay, varied from 1 day (NZM4) to curative (Colon 38), consistent with the tumour pharmacokinetic data. In cultured cell lines, SN 28049 was found in cytoplasmic bodies, suggesting that drug sequestration could contribute to tumour pharmacokinetics.
CONCLUSION: SN 28049 shows dramatic differences in both tumour AUC and antitumour activity against different tumours. These differences point to the presence of a tumour-specific uptake and retention mechanism.
Authors:
Pradeep B Lukka; Ying Yi Chen; Graeme J Finlay; Wayne R Joseph; Emma Richardson; James W Paxton; Bruce C Baguley
Related Documents :
902705 - In vivo synchronization of haemopoietic stem cells with hydroxyurea.
18650315 - Sex-related differences in activity of lower urinary tract in response to intravesical ...
19654325 - Suppression of tumor angiogenesis by galpha(13) haploinsufficiency.
18054055 - Measurement of the digit lengths and the anogenital distance in mice.
9486005 - Transforming growth factor beta 1 and interleukin 4 induced alpha smooth muscle actin e...
22393105 - Effect of angiostatin on 1,2-dimethylhydrazine-induced colon cancer in mice.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-9-14
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  -     ISSN:  1432-0843     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2013-9-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Histones and lung cancer: are the histone deacetylases a promising therapeutic target?
Next Document:  Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.